X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.fiercepharma.com/pharma/kyowa-kirin-pays-100m-partner-bridgebio-potential-dwarfism-drug
https://www.globenewswire.com//news-release/2023/12/13/2795471/0/en/BridgeBio-Announces-First-Child-Dosed-in-PROPEL-3-its-Phase-3-Clinical-Trial-for-Infigratinib-in-Children-with-Achondroplasia.html
https://www.globenewswire.com//news-release/2023/10/25/2766926/0/en/LianBio-Announces-Presentation-of-Data-from-Phase-2a-Study-of-Infigratinib-in-Patients-with-Gastric-Cancer-at-ESMO-Congress-2023.html
https://www.globenewswire.com//news-release/2023/09/06/2738260/0/en/BridgeBio-Pharma-Announces-Positive-Feedback-from-the-U-S-FDA-and-EU-EMA-on-the-Regulatory-Path-for-a-Pivotal-Phase-3-Trial-of-Infigratinib-in-Children-with-Achondroplasia.html
https://www.globenewswire.com/news-release/2023/06/20/2690942/0/en/BridgeBio-Pharma-Presents-Updated-Six-Month-Results-from-its-Phase-2-Cohort-5-Trial-of-Infigratinib-in-Achondroplasia-at-the-Endocrine-Society-ENDO-2023-Annual-Conference.html
https://www.globenewswire.com/news-release/2023/06/08/2684629/0/en/BridgeBio-Pharma-to-Present-Updated-Six-Month-Results-from-its-Phase-2-Cohort-5-Study-of-Infigratinib-in-Achondroplasia-in-a-Late-Breaker-Oral-Presentation-at-the-Endocrine-Society.html
https://www.globenewswire.com/news-release/2023/06/06/2683311/0/en/LianBio-Announces-Topline-Results-from-Phase-2a-Proof-of-Concept-Trial-Evaluating-Infigratinib-in-Patients-with-Gastric-Cancer-Receipt-of-Breakthrough-Therapy-Designation-in-China.html
https://www.globenewswire.com/news-release/2021/12/21/2355849/0/en/Helsinn-Group-Announces-European-Medicines-Agency-s-EMA-Acceptance-for-review-of-the-Marketing-Authorization-Application-MAA-for-Infigratinib-for-Patients-with-Cholangiocarcinoma-w.html
https://www.globenewswire.com/news-release/2020/05/29/2040840/0/en/BridgeBio-Pharma-s-QED-Therapeutics-Presents-Data-on-Infigratinib-in-Cholangiocarcinoma-and-Urothelial-Carcinoma-at-the-American-Society-of-Clinical-Oncology-2020-Virtual-Scientifi.html
Market Place
Share 
